Perbandingan Efektivitas dan Efek Samping Antivirus Favipiravir dan Remdesivir Pada Pasien COVID-19

Luqman Nul Haqim, Antonoius Adji Prayitno Setiadi

Sari


ABSTRACT

 

Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2). Symptoms are divided into asymptomatic, mild, moderate, severe and critical. In patients with moderate symptoms, antiviral therapy is given, including favipiravir and remdesivir. This study aims to look at the effectiveness and side effects of the two drugs. This study was a cross-sectional study involving all COVID-19 patients with moderate symptoms who were treated at the Husada Utama Hospital in Surabaya from January to December 2021. Patient data was taken based on medical record data. Data analysis used univariate and bivariate techniques. There were 59 patients who met the inclusion and exclusion criteria. There were 32 patients using favipiravir and 27 patients using remdesivir. In this study, there were no significant differences regarding the effectiveness and side effects between the use of favipiravir and remdesivir. However, the use of favipiravir was significantly shorter than remdesivir (p = 0.015). The conclusion in this study was that there were no significant differences in terms of effectiveness and side effects between the use of favipiravir and remdesivir in patients with moderate symptoms of COVID-19.

 

Keywords: Favipiravir, Remdesivir, COVID-19, Moderate Degree

 

 

ABSTRAK

 

Coronavirus Disease-2019 (COVID-19) merupakan penyakit menular yang disebabkan oleh Severe Acute Respiratory Syndrom Coronavirus-2 (SARS-Cov-2). Gejala yang ditimbulkan dibagi menjadi tanpa gejala, ringan, sedang, berat dan kritis. Pada pasien dengan gejala sedang terapi antivirus yang diberikan antara lain favipiravir dan remdesivir. Penelitian ini bertujuan untuk melihat efektivitas dan efek samping dari kedua obat tersebut. Penelitian ini merupakan penelitian cross sectional yang melibatkan seluruh pasien COVID-19 dengan gejala sedang yang dirawat di rumah sakit Husada Utama kota Surabaya pada periode Januari sampai dengan Desember 2021. Data pasien diambil berdasarkan data rekam medis. Analisis data menggunakan teknik univariat dan bivariat. Terdapat 59 pasien yang memenuhi kriteria inklusi dan eksklusi. Pasien yang menggunakan favipiravir sebanyak 32 pasien dan yang menggunakan remdesivir sebanyak 27 pasien. Dalam penelitian ini tidak terdapat perbedaan yang signifikan terkait efektivitas dan efek samping antara penggunaan favipiravir dan remdesivir. Namun penggunaan favipiravir secara signifikan lebih singkat dibandingkan remdesivir (p = 0,015). Kesimpulan dalam penelitian ini adalah tidak terdapat perbedaan yang signifikan terkait efektivitas dan efek samping antara penggunaan favipiravir dan remdesivir pada pasien COVID-19 gejala sedang.

 

Kata Kunci: Favipiravir, Remdesivir, COVID-19, Derajat Sedang

 


Teks Lengkap:

Download Artikel

Referensi


Abbas A Et Al., Cellular And Molecular Immunology, 9th. Saunders Elsevier. 2018.

Aesyrahami, A. N. (2023). Literature Review: Analisis Efektivitas Chest Therapy Pada Anak Dengan Covid-19.

Allayna, A., Nadjib, H. A., & Tamsyah, I. (2022). Bantuan Luar Negeri Amerika Serikat Dalam Menangani Pandemi Coronavirus Disease 2019 (Covid-19) Di Indonesia Tahun 2020-2022 (Doctoral Dissertation, Sriwijaya University).

Burhanuddin, A. I., Massi, M. N., Thahir, H., Razak, A., & Surungan, T. (Eds.). (2020). Merajut Asa Di Tengah Pandemi Covid-19 (Pandangan Akademisi Unhas). Deepublish.

Damayanti H, I. G. (2021). The Effectiveness And Safety Of Favipiravir In Covid-19 Hospitalized Patients At Tertiary Referral Hospital Bali Indonesia. Fkm Ui.

Deva Putra, P. R. A. D. A. N. A. (2022). Aplikasi Deep Breathing Exercise Pada Pasca Covid 19 (Doctoral Dissertation, Universitas Al-Irsyad Cilacap).

Fitriani, N. I. (2020). Tinjauan Pustaka Covid-19: Virologi, Patogenesis, Dan Manifestasi Klinis. Jurnal Medika Malahayati, 4(3), 194-201.

Gennaro, F. Di, Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020). Coronavirus Diseases ( Covid-19 ) Current Status And Future Perspectives : A Narrative Review. International Journal Of Environmental Research And Public Healthenvironmental Research And Public Health, 17(2690), 1–11. Https://Doi.Org/10.3390/Ijerph170 82690.

Haqim, L. N., & Setiadi, A. A. P. (2023). Perbandingan Efektivitas Dan Efek Samping Antivirus Favipiravir Dan Remdesivir Pada Pasien Covid-19. Manuju: Malahayati Nursing Journal, 5.

Hasmono Et Al., 2022. Study Of Effectiveness And Side Effect Of Favipiravir Therapy On Mild And Moderate Covid-19 Patients. Jurnal Kesehatan Vol.15 No. 2 Desember, 2022. Doi: 10.24252/Kesehatan.V15i2.29380

Hassanipour Et Al., 2021. The Efficacy And Safety Of Favipiravir In Treatment Of Covid 19: A Systematic Review And Meta Analysis Of Clinical Trials. Scientific Reports (2021) 11:11022. Https://Doi.Org/10.1038/S41598-021-90551-6

Joshi Et Al., (2020). Role Of Favipiravir In The Treatment Of Covid-19. International Journal Of Infectious Diseases 102 (2021) 501–508.

Joshi Et Al., 2022. Real-World Experience With Favipiravir For The Treatment Of Mild-To-Moderate Covid-19 In India. Pragmatic And Observational Research 2022:13 33–41. Https://Doi.Org/10.2147/Por.S364066

Morris Am, Jüni P, Odutayo A, Et Al. Remdesivir For Hospitalized Patients With Covid-19. Science Briefs Of The Ontario Covid19 Science Advisory Table. 2021;2(27). Https:// Doi.Org/10.47326/Ocsat.2021.02.27.1.

Mukherjee S, Pahan K. Is Covid-19 Gender-Sensitive? J Neuroimmune Pharmacol Off J Soc Neuroimmune Pharmacol. 2021 Mar;16(1):38-47.

Perhimpunan Dokter Paru Indonesia (Pdpi), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (Perki), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (Papdi), Perhimpunan Dokter Anestesiologi Dan Terapi Intensif Indonesia (Perdatin) Idai (Idai). Pedoman Tatalaksana Covid-19 Edisi 3 Desember 2020. Jakarta; 2020. 1-138 P.

Rezkita, B. E., Irving, S., Pribadi, R. R., & Simadibrata, M. (2022). Efektivitas Efikasi Pemberian Antivirus Favipiravir Pada Pasien Covid-19: Evidence Based Case Report. Keluwih: Jurnal Kesehatan Dan Kedokteran, 3(2), 100-107.

Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Sinto, R., … Yunihastuti, E. (2020). Coronavirus Disease 2019 : Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia, 7(1), 45–67.

Tanjung, M. S., & Sitepu, R. (2021). Epidemiologi Deskriptif Coronavirus Disease 2019 (Covid-19) Di Indonesia Pada Tahun 2020. Ibnu Sina: Jurnal Kedokteran Dan Kesehatan-Fakultas Kedokteran Universitas Islam Sumatera Utara, 20(2), 179-191.

Terkes, V.; Lisica, K.; Marusic, M.; Verunica, N.; Tolic, A.; Morovic, M. Remdesivir Treatment In Moderately Ill Covid-19 Patients: A Retrospective Single Center Study. J. Clin. Med. 2022, 11, 5066. Https:// Doi.Org/10.3390/Jcm11175066

World Health Organization (Who). Naming The Coronavirus Disease (Covid-19) And The Virus That Causes It [Internet]. Available From: Https://Www.Who.Int/Emergencies/Diseases/Novelcoronavirus-2019/Technical-Guidance/ Naming-Thecoronavirus-Disease-(Covid-2019)-And-The-Virus-Thatcauses-It.




DOI: https://doi.org/10.33024/mnj.v5i6.8743

Refbacks

  • Saat ini tidak ada refbacks.


Penerbit: Universitas Malahayati

 Creative Commons License

Semua artikel dapat digunakan dibawah lisensi Creative Commons Attribution-ShareAlike 4.0 International License